tpst-1120
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 20, 2019 (NCT03829436)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Cholangiocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms, Castration-Resistant · Phase 1
- Sarcoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
ppara antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06680258 | Phase 3 | Mar 29, 2025 | Roche, Tempest Therapeutics |
| NCT03829436 | Phase 1 | Mar 20, 2019 | Tempest Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tempest Therapeutics | For profit | 2 | 2 | 2 | 2019 |
| Roche | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1